Home FOR AUTHORS Neoplasma Ahead of print Neoplasma Vol.69, No.1, p.113–122, 2022

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.69, No.1, p.113–122, 2022

Title: LDLR promotes growth and invasion in renal cell carcinoma and activates the EGFR pathway
Author: Gui-Ming Zhang, Wei Chen, Yu Yao, Lei Luo, Li-Jiang Sun

Abstract: Previous studies identified an association of low-density lipoprotein (LDL) levels and LDL receptor (LDLR) with renal cell carcinoma (RCC) development. This study investigated the expression and roles of LDLR in RCC. LDLR expression was examined in clear cell RCC (ccRCC) and adjacent normal kidney tissues, and its clinicopathological significance was analyzed. The role of LDLR in RCC cell proliferation, cell cycle, and invasion were assessed in RCC cells with LDLR stable knockdown. LDLR expression was higher in ccRCC tissues than in normal kidney tissues and increased with RCC progression. LDLR knockdown in RCC cells inhibited cell growth, migration and invasion, and induced G1/S cell cycle arrest. We identified an interaction between LDLR and EGFR, and EGFR signaling protein expression was reduced after LDLR knockdown. Our findings reveal that LDLR plays an important role in RCC carcinogenesis, suggesting that LDL and LDLR might be potential targets for therapeutic intervention in RCC.

Keywords: renal cell carcinoma; low-density lipoprotein receptor; cell proliferation; invasion; EGFR
Published online: 30-Nov-2021
Year: 2022, Volume: 69, Issue: 1 Page From: 113, Page To: 122
doi:10.4149/neo_2021_210607N762


download file



© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.